SOURCE: Serenex

October 09, 2007 09:00 ET

Serenex to Present at Biotechnology Industry Organization (BIO) Investor Forum 2007

DURHAM, NC--(Marketwire - October 9, 2007) - Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, announced today that Dr. Richard Kent, chief executive officer, is scheduled to present at the Biotechnology Industry Organization (BIO) Investor Forum taking place in San Francisco at The Palace Hotel.

On Thursday, October 11 at 9:30 am PDT, Dr. Kent will present an overview of the company including recent clinical data relating to SNX-5422, the Company's oral, small molecule, phase 1 Hsp90 inhibitor. A replay of the presentation will be available under the "News" section of the Serenex website (www.serenex.com) approximately 12 hours after the presentation for a period of 90 days.

About Serenex

Serenex is an integrated drug discovery and development company and a leader in the discovery and development of small molecule Hsp90 inhibitors. Serenex has a novel small molecule inhibitor of Heat Shock Protein 90 (Hsp90), SNX-5422, which is in phase 1 clinical trials. SNX-5422 was developed from the Company's Hsp90 Product Platform, a proprietary collection of several hundred potent small molecule Hsp90 inhibitors. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic and other proteins and is believed to play a key role in cancer, inflammatory diseases, fungal infection resistance, viral diseases and neurodegenerative diseases such as Alzheimer's. Serenex has ongoing pre-clinical programs in all of these areas. Additionally, Serenex is developing SNX-1012, a product for oral mucositis in solid tumor patients scheduled to complete phase 2 clinical trials in early 2008. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.

Contact Information

  • CONTACT:
    Ian Howes
    CFO & Sr. V.P. Corporate Development
    Serenex, Inc.
    919/281-6001
    Email Contact

    Michelle Linn
    Linnden Communications.
    508/419-1555
    Email Contact